Alto Neuroscience (ANRO)
Develops neuropsychiatric drug candidates for biomarker-defined patient populations.
Something off on this page? Send us feedback.
Develops clinical-stage drug candidates for neuropsychiatric disorders using brain-based biomarkers to identify likely responders. Its pipeline spans depressive disorders, schizophrenia, and Parkinson's disease, with ALTO-207 identified as its most advanced program.
Builds clinical-stage treatments for major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease. Its platform combines neurocognitive assessments, EEG, wearable data, and analytics to define patient groups more likely to respond to a candidate. Clinical studies are designed around objective cognitive or EEG markers.
The pipeline includes acquired ALTO-207, a fixed-dose pramipexole/ondansetron combination identified as its most advanced program. Its workforce is concentrated in the United States, with a small presence in Australia. Development depends on clinical execution and data from active programs after ALTO-100 and ALTO-101 missed primary endpoints in separate trials.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | H.C. Wainwright | Reiterate | Buy | $50 | $55 | |
| Aug 13, 2026 | BTIG | Reiterate | Buy | $28 | $37 | |
| May 27, 2026 | H.C. Wainwright | Target | $50 | |||
| May 18, 2026 | Robert W. Baird | Target | $16 | $36 | ||
| May 14, 2026 | Wedbush | Reiterate | Neutral | $24 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $243.7M · Total debt $7.0M · Total assets $254.1M · Shareholders' equity $219.2M
- Revenue
- $0
- Operating income
- −$29.1M
- Net income
- −$27.6M
No dividends on record.
| Institutions114 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 76.45% | 26.83M shares | |
| Insiders2 holders · as of May 15, 2026 | 3.07% | 1.08M shares | |
| Strategic holders1 holder · as of Jul 20, 2026 | 6.36% | 2.23M shares | |
| Otherremainder | ≈ 14.12% | 4.95M shares |
35.09M company shares as of Aug 23, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (39.24M in the company's Sep 3, 2026 report, 35.09M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alpha Wave Global, LPInstitution | 10.57% | 3.71M | 13Fas of Mar 31, 2026 |
Commodore Capital LPInstitution | 7.76% | 2.72M | 13Fas of Mar 31, 2026 |
Sirenia Capital Management LPInstitution | 7.38% | 2.59M | 13Gfiled May 15, 2026 ↗ |
EcoR1 Capital, LLCStrategic | 6.36% | 2.23M | 13Gfiled Jul 20, 2026 ↗ |
Vestal Point Capital, LPInstitution | 5.88% | 2.06M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Axsome Therapeutics
Commercial major-depressive-disorder therapy with AUVELITY
- AbbVie
Commercial psychiatry overlap across MDD, bipolar depression and schizophrenia
- Atai Beckley
Late-stage treatment-resistant-depression pipeline with BPL-003
- Xenon Pharmaceuticals
Phase 3 MDD and bipolar-depression pipeline with azetukalner
- Neurocrine Biosciences
Schizophrenia pipeline led by Phase 3 direclidine
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alto Neuroscience | $36.64 | +0.14% | $1.29B | — | — | — | — |
| Axsome Therapeutics | $212.18 | +1.08% | $10.80B | — | 1,800.7 | 13.9 | +44.2% |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Atai Beckley | $7.32 | −0.39% | $2.72B | — | — | 607.9 | +137.0% |
| Xenon Pharmaceuticals | $60.60 | +0.60% | $5.82B | — | — | — | — |
| Neurocrine Biosciences | $157.77 | +0.64% | $15.87B | 23.1 | 17.3 | 4.7 | +39.5% |
| Median | 48.4 | 17.3 | 10.5 | +41.8% |